Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses

(2019) Victoria Mandilaras et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer

(2019) Chae Young Han et al.   MOLECULAR CARCINOGENESIS

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

(2019) Lawrence A. Donehower et al.   Cell Reports

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers

(2019) Musaffe Tuna et al.   BRITISH JOURNAL OF CANCER

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

(2018) Katherine A. Hoadley et al.   CELL

Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing

(2018) Tuomas Tikkanen et al.   HUMAN MUTATION

A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation

(2018) Eran Kotler et al.   MOLECULAR CELL

p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer

(2017) Xi Wang et al.   HUMAN PATHOLOGY

TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response

(2017) Nagako Akeno et al.   MOLECULAR CANCER THERAPEUTICS

ClinVar: improving access to variant interpretations and supporting evidence

(2017) Melissa J Landrum et al.   NUCLEIC ACIDS RESEARCH

TP53Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response

(2016) Ge Zhou et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Inherited Mutations in Women With Ovarian Carcinoma

(2016) Barbara M. Norquist et al.   JAMA Oncology

Mutant p53: One, No One, and One Hundred Thousand

(2015) Dawid Walerych et al.   Frontiers in Oncology

TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade

(2014) Bernard Leroy et al.   HUMAN MUTATION

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

(2014) PAVLA BRACHOVA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

(2013) Ruth Perets et al.   CANCER CELL

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma

(2013) Hyo Jeong Kang et al.   PLoS One

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Mutant p53 cooperates with ETS2 to promote etoposide resistance

(2012) P. M. Do et al.   GENES & DEVELOPMENT

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma

(2012) Jessica N McAlpine et al.   MODERN PATHOLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

(2011) T. Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

(2010) Tom Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

(2007) R. SALANI et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER